{"id":"W4410935761","doi":"10.1016/j.annonc.2025.05.010","title":"Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"EMD Serono; Genentech; Foundation Medicine; LEO Pharma; Medac; Ipsen; Ono Pharmaceutical; Genesis Pharma; Cilag; Astellas Pharma; Seagen; Teva Pharmaceutical Industries; Gilead Sciences; Daiichi Sankyo Europe; Exelixis; Sanofi; Merck; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Merck Healthcare KGaA","keywords":"Javelin; Avelumab; Medicine; Urothelial carcinoma; Interim analysis; Interim; Oncology; Internal medicine; Urology; First line treatment; Metastatic Urothelial Carcinoma; Urothelial cancer; Bladder cancer; Chemotherapy; Immunotherapy; Cancer; Clinical trial; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007069195,0.001269297,0.005133115,0.0005103421,0.0005492148,0.002743803,0.001569725,0.001453688,0.005275981],"category_scores_gemma":[0.00532097,0.000799611,0.008098332,0.0006704064,0.0007297262,0.002424448,0.0008320981,0.005170033,0.0008835846],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00166858,"about_ca_system_score_gemma":0.002317094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001525617,"about_ca_topic_score_gemma":0.005055065,"domain_scores_codex":[0.9959074,0.002456415,0.0001710172,0.0005028094,0.0003219983,0.0006404427],"domain_scores_gemma":[0.9970849,0.001213862,0.0005796422,0.0004514301,0.0001756065,0.000494525],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8851025,0.00224565,0.01201369,0.0008502923,0.01906757,0.0001071878,0.0001461602,0.007839127,0.0019212,0.0009071567,0.008064381,0.06173516],"study_design_scores_gemma":[0.536629,0.2454404,0.1031653,0.0008496632,0.06024184,0.0005569304,0.0004560971,0.02172127,0.005122356,0.004905092,0.02062888,0.000283099],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9498629,0.02039005,0.003539204,0.00341733,0.001477944,0.001151063,0.00947637,0.0002390881,0.01044603],"genre_scores_gemma":[0.9747635,0.002938175,0.00299075,0.002453312,0.0004919556,0.0009747109,0.006236346,0.00009864369,0.009052645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007069195,"threshold_uncertainty_score":0.03738594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03714372364506753,"score_gpt":0.3575011504346939,"score_spread":0.3203574267896264,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}